Basics
Description
- A rash caused by a hypersensitivity reaction:
- May occur in response to various medications, infections, or other illness
- Erythema multiforme (EM) minor:
- Typical target lesions
- Edematous papules
- Usually distributed peripherally
- Benign, self-limited rash generally not associated with acute, serious illness
- EM major
- Also called bullous EM
- Target lesions
- Edematous papules
- Also with peripheral distribution
- Involves 1 or more mucous membranes
- <10% total body surface area of epidermal detachment
- Differentiate from:
- Stevens-Johnson syndrome (SJS):
- Also <10% TBSA epidermal detachment
- Often widespread blisters over trunk and face
- Mucosal involvement
- Toxic epidermal necrolysis (TEN)
- >30% TBSA epidermal detachment
- EM is now considered a different entity from SJS and EM
- Most often affects children and young adults (>50% younger than 20 yr)
- Males are affected more often than females.
Etiology
- Hypersensitivity reaction, probably transient autoimmune defect
- Herpes simplex virus (HSV) is the most common precipitant (>70%).
- Other causes include:
- Idiopathic
- Medications
- Penicillin
- Sulfur based
- Phenytoin
- Barbiturates
- NSAIDs
- Vaccines
- Diphtheria-tetanus
- Hepatitis B
- Smallpox
- Malignancy
- Infection
- HIV
- CMV
- Hepatitis C
- Mycoplasma infections
Diagnosis
Signs and Symptoms
History
- Prodrome: Infrequent systemic symptoms (mild fever/malaise), antecedent HSV in most cases (within 3 wk)
- Usually not associated with severe systemic illness
Physical Exam
Characteristic rash:
- Lesions:
- Symmetric dull red macules and papules
- Evolve into round, well-demarcated target lesions with central clearing
- No epidermal necrosis with EM minor
- Multiforme refers to the evolution of the rash through various stages at different times.
- Distribution:
- Extremities
- Dorsal hands and feet
- Extensor surfaces
- Elbows and knees.
- 1 of the few rashes that may involve palms and soles
- Spread: From extremities toward trunk
- Mucosal involvement: Minor blistering or erosions of 1 mucosal surface (lips/mouth)
- Duration: Usually 1-4 wk, but may become chronic or recurrent
Essential Workup
Complete history and physical exam, with special attention to the skin, genitourinary system, recent infectious symptoms, and recent medications
Diagnosis Tests & Interpretation
Lab
No specific lab tests needed
Imaging
No specific imaging is helpful.
Diagnostic Procedures/Surgery
- Skin biopsy reveals mononuclear cell infiltrate around upper dermal blood vessels, without leukocytoclastic vasculitis and necrosis of epidermal keratinocytes.
- Biopsy is not necessary in most cases.
Differential Diagnosis
- Systemic lupus erythematosus
- Fixed drug eruption
- Pityriasis rosea
- Secondary syphilis
- Erythema migrans
- Urticaria
- SJS
- TEN
- Vasculitis
- Viral exanthem
Treatment
Pre-Hospital
Not contagious and does not require isolation or postexposure prophylaxis for exposed personnel
Initial Stabilization/Therapy
Generally benign and self-limited, requiring no initial stabilization
Ed Treatment/Procedures
- Attempt to identify, treat, or remove underlying cause or precipitant.
- Symptomatic: Cool compresses, antipruritics
Medication
- Antiviral agents:
- Acute EM
- Treat within 48 hr of onset
- May not impact clinical course
- Prevention of recurrent EM
- Acyclovir 400 mg PO BID
- Valacyclovir 500 mg PO BID
- Famciclovir 250 mg PO BID
- Antipruritic agents:
- Cetirizine (Zyrtec): 10 mg/d (peds: 2.5-5 mg) PO
- Diphenhydramine: 25-50 mg (peds: 5 mg/kg/24h) PO q6-8h
- Hydroxyzine: 25 mg PO q6-8h (peds: 2 mg/kg/24h div. q6-8h)
- Anesthetic for oral lesions
- Oral corticosteroids:
- Reserved for severe mucosal disease
- Prednisone 40-60 mg PO QD tapered over 2-3 wk
- Medium-potency topical corticosteroids:
- Triamcinolone 1% apply BID-QID
- Do not use on face or eyelids
- Low-potency topical corticosteroids
- For face or intertriginous regions
- Hydrocortisone 1% apply BID-QID
First Line
- Topical corticosteroids (low to medium potency)
- Antipruritics
Second Line
- Antivirals
- Oral corticosteroids
Follow-Up
Disposition
Admission Criteria
- Admission is not needed unless required for another concurrent disorder.
- Unable to take PO fluids secondary to mucosal lesions
Discharge Criteria
EM is generally a benign disorder that does not require admission.
Issues for Referral
- Patients should be referred to a dermatologist if the diagnosis is uncertain or the rash is atypical or severe.
- Refer immediately to ophthalmologist if ocular involvement
Follow-Up Recommendations
- Follow-up with primary care physician within 1 wk to assess:
- Further evaluation of underlying conditions (infection, medications, malignancy, etc.)
- Progression or resolution of rash
- Follow-up with a dermatologist within 1 wk if the diagnosis is uncertain.
Pearls and Pitfalls
- In patients with severe systemic illness, a more serious diagnosis should be considered, such as SJS or TEN.
- Most patients with EM have underlying HSV infection.
- Secondary syphilis may produce similar lesions on the palms and soles.
- Reassure patients that the rash of EM is benign and self-limited.
Additional Reading
- Dyall-Smith D. Erythema multiforme. Available at www.dermnetnz.org. Accessed on July 1, 2011.
- Lamoreux MR, Sternbach MR, Hsu WT. Erythema multiforme. Am Fam Physician. 2006;74:1883-1888.
- Plaza J. Erythema multiforme. Available at www.emedicine.com. Accessed on July 29, 2011.
- Scully C, Bagan J. Oral mucosal diseases: Erythema multiforme. Br J Oral Maxillofac Surg. 2008;46:90-95.
- Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: A review for the practicing dermatologist. Int J Dermatol. 2012;51:889-902.
- Wetter DA. Pathogenesis, clinical features, and diagnosis of erythema multiforme. In: Callen J, ed. UpToDate. Waltham, MA: UpToDate; 2013.
- Wetter DA. Treatment of erythema multiforme. In: Callen J, ed. UpToDate. Waltham, MA: UpToDate; 2013.
See Also (Topic, Algorithm, Electronic Media Element)
- Herpes
- Stevens-Johnson Syndrome
- Toxic Epidermal Necrolysis
Codes
ICD9
- 695.10 Erythema multiforme, unspecified
- 695.13 Stevens-Johnson syndrome
- 695.15 Toxic epidermal necrolysis
- 695.19 Other erythema multiforme
- 695.11 Erythema multiforme minor
- 695.12 Erythema multiforme major
- 695.14 Stevens-Johnson syndrome-toxic epidermal necrolysis overlap syndrome
- 695.1 Erythema multiforme
ICD10
- L51.1 Stevens-Johnson syndrome
- L51.2 Toxic epidermal necrolysis [Lyell]
- L51.9 Erythema multiforme, unspecified
- L51.8 Other erythema multiforme
- L51.3 Stevens-Johnson synd-tox epdrml necrolysis overlap syndrome
SNOMED
- 36715001 erythema multiforme (disorder)
- 73442001 Stevens-Johnson syndrome (disorder)
- 23067006 Lyells toxic epidermal necrolysis, subepidermal type (disorder)
- 297942002 Drug-induced erythema multiforme (disorder)
- 402971008 Erythema multiforme due to mycoplasma infection (disorder)